Recently published data from the ZUMA-1 and JULIET trials suggest that CD19-directed chimeric antigen receptor (CAR) T cell therapy can provide durable remissions, with a low risk of relapse or progression, in 30–40% of patients with relapsed and/or refractory aggressive large B cell lymphoma. Two-year follow-up of the ZUMA-1 clinical trial has not revealed any unexpected toxicities, but further safety monitoring will be needed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells
Journal of Biomedical Science Open Access 31 May 2023
-
Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer
Cancer Immunology, Immunotherapy Open Access 27 September 2022
-
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Journal of Hematology & Oncology Open Access 02 October 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019).
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
Crump, M. et al. Outcomes in refractory diffuse large B cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800–1808 (2017).
Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T cell therapy in refractory large B cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
Schuster, S. J. et al. Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B cell lymphoma (r/rDLBCL) treated with tisagenlecleucel on the JULIET study [abstract 4190]. Presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA (2018).
Locke, F. L. et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-cel) in patients (Pts) with refractory large B cell lymphoma. J. Clin. Oncol. 36 (Suppl. 15), 3003 (2018).
Lee, D. W. et al. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. https://doi.org/10.1016/j.bbmt.2018.12.758 (2018).
Nastoupil, L. J. et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory large B cell lymphoma: real world experience. Blood 132, 91 (2018).
Abramson, J. et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J. Clin. Oncol. 36 (Suppl. 15), 7505 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.G.M. has participated in and received honoraria for clinical advisory boards for Juno/Celgene, Kite/Gilead and Novartis. The employing institution of D.G.M. receives clinical trial research support from Juno/Celgene and Kite/Gilead.
Rights and permissions
About this article
Cite this article
Maloney, D.G. Anti-CD19 CAR T cell therapy for lymphoma — off to the races!. Nat Rev Clin Oncol 16, 279–280 (2019). https://doi.org/10.1038/s41571-019-0183-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0183-7
This article is cited by
-
A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells
Journal of Biomedical Science (2023)
-
Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer
Cancer Immunology, Immunotherapy (2023)
-
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Journal of Hematology & Oncology (2020)
-
Tinkering in the garage — tuning CARs for safety
Nature Reviews Clinical Oncology (2019)